Bezuclastinib plus Sutent could become standard of care in second-line GIST.

After more discontinuations, a new deal brings in fresh blood.

The CD70-targeting CTX131 heads for the scrapheap.

Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.

Inhibrx reveals three deaths in phase 1, but all predate screening protocols.

BG-75202 features among several projects starting first-in-human trials.